Drug Alerts and Special Reports

Key reimbursement alerts for office-administered drugs — C-Code, J-Code, NDC, and NCCN alerts plus pricing updates, sent on behalf of pharma manufacturers.

Subscribe To Newsletter

FDA Approved 03/10/2023

Now Approved: SYFOVRE (pegcetacoplan injection) - 3/2/23

Now Approved: SYFOVRE™ (pegcetacoplan injection) Email content sponsored by Apellis Pharmaceuticals, Inc. Email content sponsored by Apellis Pharmaceuticals, Inc. NOW APPROVED: The first and only treatment proven to slow lesion growth rate in GA secondary to AMD 1 SYFOVRE (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) SELECT SAFETY INFORMATION SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with…

Now Available 03/10/2023

Now Available: Orenitram Titration Kits for Simplified Dosing - 3/1/23

Now Available: Orenitram® Titration Kits for Simplified Dosing Orenitram Titration Kits for Simplified Dosing 96 --> Orenitram Titration Kits for Simplified Dosing We are pleased to announce the availability of the Orenitram Titration Kit , designed to simplify dosing and titration so patients can reach the target dose prescribed by their healthcare provider. *De novo patients who are starting Orenitram on a TID dosing schedule are eligible for the Titration Kit. Restrictions apply. 3 MONTHLY KITS 4 WEEKLY BOXES PER MONTH 7…

Pricing 03/10/2023

Price Change for HEPLISAV-B, Hepatitis B Vaccine (Recombinant) - 2/23/23

Announcing a price change for HEPLISAV-B®, {Hepatitis B Vaccine (Recombinant), Adjuvanted} This message is being sent by www.BuyandBill.com on behalf of Dynavax Technologies Effective March 1, 2023 the pricing of HEPLISAV-B ® will change as outlined below. Please take a moment to update any of your reimbursement, billing, and ordering systems to reflect this change. HEPLISAV-B® NDC Code and Pricing: CPT Code 11 Digit NDC Code Effective Date Product Description WAC Per Package WAC Per Syringe Estimated AWP…

03/10/2023

Lamzede: New Treatment Option Available For Ultra-rare LSD - 2/22/23

New Treatment Option Available For Ultra-rare LSD We are pleased to announce the recent FDA approval of Lamzede® (velmanase alfa-tycv); a recombinant human lysosomal alpha-mannosidase indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.1 AM patients have waited a long time for a treatment option and Chiesi is proud to have it now available for them. Dosage and administration: The recommended dosage is 1mg/kg (actual body weight) administered once every week as an…

03/10/2023

J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G - 2/1/23

To: Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) Effective "> J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) From: BuyandBill.com < [email protected] > To: Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) Effective January 1, 2023: J1932…

03/09/2023

J1954, injection, leuprolide, (Lutrate), 7.5 mg, is available for all sites of care - 1/4/23

Effective January 1, 2023: J1954 The unique HCPCS code for Cipla USA's LEUPROLIDE ACETATE INJECTION DEPOT (Leuprolide Acetate for Depot Suspension) Effective January 1, 2023: J1954, injection, leuprolide, (Lutrate), 7.5 mg, is available for all sites of care. J1954 is a unique HCPCS code for Cipla's version of LEUPROLIDE ACETATE INJECTION DEPOT (Leuprolide Acetate for Depot Suspension) and sh ould not be used for billing other leuprolide formulations. HCPCS Code HCPCS Code Descriptor NDC Number Strength WAC Per Package HCPCS Units Per…

03/08/2023

New Indication for Adcetris J9042 - 1/3/23

Announcing a new approval for pediatric patients 2 years and older with previously untreated high risk classical Hodgkin Lymphoma 96 96 Important Safety Information Prescribing Information ADCETRIS ® (brentuximab vedotin) for injection is now approved for use in pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide. 1 Indication and Recommended Dosage ADCETRIS is a CD30-directed antibody-drug…

02/14/2023

Teva Products: Updated HCPCS Coding Information - 12/19/22

Teva Products: Updated HCPCS Coding Information Updated HCPCS* Coding Information for Teva Products Effective January 1, 2023, providers should use the new, permanently assigned HCPCS codes for these products, as shown in the tables below. Old/temporary HCPCS codes should not be used after December 31, 2022. Please update your claims processing system and any applicable coverage policies and fee schedules. † Fosaprepitant for Injection…

Pricing 02/14/2023

Announcing a Price Change for Paragard (intrauterine copper contraceptive) - 12/16/22

Announcing a Price Change for Paragard® (intrauterine copper contraceptive) Paragard Customer, Effective December 31, 2022, the pricing of Paragard will change as outlined below. Please take a moment to update any of your reimbursement, billing, and ordering systems to reflect this change. PARAGARD PRICING AND CODING INFORMATION: HCPCS Code Labeler 11 Digit NDC Price Effective Date Product Description WAC Estimated AWP J7300…

Pricing 02/14/2023

Important Price Change Announcement for Photrexa - 12/13/22

Important Price Change Announcement for Photrexa® This email is being sent by BuyandBill.com on behalf of Glaukos ® , Inc. Announcing New Pricing for Photrexa ® Cross-Linking Kit As of January 1, 2023 Item Code/Price Description HCPCS Code J2787 Riboflavin 5'-phosphate, ophthalmic solution, up to 3 ml NDC Number 25357-0025-03 A cross linking kit contains one Photrexa Viscous 3 ml single-patient use syringe and one Photrexa solution 3 ml…

1 … 151617 18

No alerts match your filters.